Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management
<i>Background and Objectives</i>: Janus kinase inhibitors (JAKi) have significantly advanced the treatment of various dermatological conditions by modulating the JAK-STAT signalling pathway. While these inhibitors have proven effective, they also pose challenges due to associated increas...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/1/54 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588029883056128 |
|---|---|
| author | Giovanni Paolino Mario Valenti Andrea Carugno Matteo Bianco Dario Didona Matteo Riccardo Di Nicola Pier Luigi Acutis Carmen Cantisani Vittoria Giulia Bianchi Nicola Zerbinati Alessandra Narcisi Antonio Costanzo Santo Raffaele Mercuri |
| author_facet | Giovanni Paolino Mario Valenti Andrea Carugno Matteo Bianco Dario Didona Matteo Riccardo Di Nicola Pier Luigi Acutis Carmen Cantisani Vittoria Giulia Bianchi Nicola Zerbinati Alessandra Narcisi Antonio Costanzo Santo Raffaele Mercuri |
| author_sort | Giovanni Paolino |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: Janus kinase inhibitors (JAKi) have significantly advanced the treatment of various dermatological conditions by modulating the JAK-STAT signalling pathway. While these inhibitors have proven effective, they also pose challenges due to associated increase in serum lipid levels and relative potential cardiovascular risks. This perspective work aims to discuss the implications of these lipid alterations proposing management strategies for patients with dermatological disorders under JAKi treatments. <i>Materials and Methods</i>: This manuscript reviews existing and recent literature on the metabolic effects of JAKi, particularly focusing on their impact on lipid profiles in patients treated for dermatological diseases. <i>Results</i>: JAK inhibitors are consistently associated with an increase in both LDL and HDL levels shortly after treatment initiation, which tend to stabilise over time. Despite these changes, there is no clear evidence linking these alterations to an increased risk of major adverse cardiovascular events (MACE), indicating a complex interaction between lipid metabolism and JAK-STAT signalling. <i>Conclusions</i>: Although JAKi may induce lipid changes in patients, raising concerns, especially in ones with existing cardiovascular risks, currently there is no proven link to increased MACE in this population. Monitoring lipid levels, alongside lifestyle modifications and possible statin use, can manage these effects without the need to stopping treatment. |
| format | Article |
| id | doaj-art-ec1847e30538431f9f60f98f165f2042 |
| institution | Kabale University |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-ec1847e30538431f9f60f98f165f20422025-01-24T13:40:24ZengMDPI AGMedicina1010-660X1648-91442025-01-016115410.3390/medicina61010054Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and ManagementGiovanni Paolino0Mario Valenti1Andrea Carugno2Matteo Bianco3Dario Didona4Matteo Riccardo Di Nicola5Pier Luigi Acutis6Carmen Cantisani7Vittoria Giulia Bianchi8Nicola Zerbinati9Alessandra Narcisi10Antonio Costanzo11Santo Raffaele Mercuri12Unit of Dermatology and Cosmetology, IRCCS Ospedale San Raffaele, 20132 Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, ItalyDepartment of Medicine and Surgery, University of Insubria, 21100 Varese, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, ItalyRare Skin Diseases Center, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, ItalyUnit of Dermatology and Cosmetology, IRCCS Ospedale San Raffaele, 20132 Milan, ItalyIstituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d’Aosta, 10154 Turin, ItalyDermatologic Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, La Sapienza University of Rome, 00185 Rome, ItalyUnit of Dermatology and Cosmetology, IRCCS Ospedale San Raffaele, 20132 Milan, ItalyDepartment of Medicine and Innovation Technology (DiMIT), University of Insubria, 21100 Varese, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, ItalyUnit of Dermatology and Cosmetology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy<i>Background and Objectives</i>: Janus kinase inhibitors (JAKi) have significantly advanced the treatment of various dermatological conditions by modulating the JAK-STAT signalling pathway. While these inhibitors have proven effective, they also pose challenges due to associated increase in serum lipid levels and relative potential cardiovascular risks. This perspective work aims to discuss the implications of these lipid alterations proposing management strategies for patients with dermatological disorders under JAKi treatments. <i>Materials and Methods</i>: This manuscript reviews existing and recent literature on the metabolic effects of JAKi, particularly focusing on their impact on lipid profiles in patients treated for dermatological diseases. <i>Results</i>: JAK inhibitors are consistently associated with an increase in both LDL and HDL levels shortly after treatment initiation, which tend to stabilise over time. Despite these changes, there is no clear evidence linking these alterations to an increased risk of major adverse cardiovascular events (MACE), indicating a complex interaction between lipid metabolism and JAK-STAT signalling. <i>Conclusions</i>: Although JAKi may induce lipid changes in patients, raising concerns, especially in ones with existing cardiovascular risks, currently there is no proven link to increased MACE in this population. Monitoring lipid levels, alongside lifestyle modifications and possible statin use, can manage these effects without the need to stopping treatment.https://www.mdpi.com/1648-9144/61/1/54atopic dermatitisalopecia areatavitiligocardiovascular riskdermatological treatmentdyslipidemia |
| spellingShingle | Giovanni Paolino Mario Valenti Andrea Carugno Matteo Bianco Dario Didona Matteo Riccardo Di Nicola Pier Luigi Acutis Carmen Cantisani Vittoria Giulia Bianchi Nicola Zerbinati Alessandra Narcisi Antonio Costanzo Santo Raffaele Mercuri Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management Medicina atopic dermatitis alopecia areata vitiligo cardiovascular risk dermatological treatment dyslipidemia |
| title | Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management |
| title_full | Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management |
| title_fullStr | Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management |
| title_full_unstemmed | Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management |
| title_short | Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management |
| title_sort | serum lipids alterations in patients under systemic jak inhibitors treatments in dermatology clinical aspects and management |
| topic | atopic dermatitis alopecia areata vitiligo cardiovascular risk dermatological treatment dyslipidemia |
| url | https://www.mdpi.com/1648-9144/61/1/54 |
| work_keys_str_mv | AT giovannipaolino serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT mariovalenti serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT andreacarugno serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT matteobianco serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT dariodidona serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT matteoriccardodinicola serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT pierluigiacutis serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT carmencantisani serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT vittoriagiuliabianchi serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT nicolazerbinati serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT alessandranarcisi serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT antoniocostanzo serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement AT santoraffaelemercuri serumlipidsalterationsinpatientsundersystemicjakinhibitorstreatmentsindermatologyclinicalaspectsandmanagement |